SZShuang Zhang

Shuang Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shuang Zhang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Li

    Department of radiology, Affiliated Hospital of Hubei University of Arts and Science, Hubei, Xiangyang, 441000, China

    2 shared publications
  • Feng Wu

    Department of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China

    2 shared publications
  • Linhan Zhai

    Department of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China

    2 shared publications
  • Shijun Jia

    Department of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China

    2 shared publications
  • Rui Zhang

    Department of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China

    1 shared publication
  • Wenzhi Lv

    Department of Artificial Intelligence , Julei Technology Company , Wuhan , Hubei , China

    1 shared publication

Latest Publications

  • Open Access

    Predicting preoperative muscle invasion status for bladder cancer using computed tomography-based radiomics nomogram

    by Rui Zhang, Shijun Jia, Linhan Zhai, Feng Wu, Shuang Zhang, Feng Li

    Objectives: The aim of the study is to assess the efficacy of the established computed tomography (CT)-based radiomics nomogram combined with radiomics and clinical features for predicting muscle invasion status in bladder cancer (BCa). Methods: A retrospective analysis was conducted using data from patients who underwent CT urography at our institution between May 2018 and April 2023 with urothelial carcinoma of the bladder confirmed by postoperative histology. There were 196 patients enrolled in all, and each was randomized at random to either the training cohort (n = 137) or the test cohort (n = 59). Eight hundred fifty-one radiomics features in all were retrieved. For feature selection, the significance test and least absolute shrinkage and selection operator (LASSO) approaches were utilized. Subsequently, the radiomics score (Radscore) was obtained by applying linear weighting based on the selected features. The clinical and radiomics model, as well as radiomics-clinical nomogram were all established using logistic regression. Three models were evaluated using analysis of the receiver operating characteristic curve. An area under the curve (AUC) and 95% confidence intervals (CI) as well as specificity, sensitivity, accuracy, negative predictive value, and positive predictive value were included in the analysis. Radiomics-clinical nomogram’s performance was assessed based on discrimination, calibration, and clinical utility. Results: After obtaining 851 radiomics features, 12 features were ultimately selected. Histopathological grading and tortuous blood vessels were included in the clinical model. The Radscore and clinical histopathology grading were among the final predictors in the unique nomogram. The three models had an AUC of 0.811 (95% CI, 0.742–0.880), 0.845 (95% CI, 0.781–0.908), and 0.896 (95% CI, 0.846–0.947) in the training cohort and in the test cohort they were 0.808 (95% CI, 0.703–0.913), 0.847 (95% CI, 0.739–0.954), and 0.887 (95% CI, 0.803–0.971). According to the DeLong test, the radiomics-clinical nomogram’s AUC in the training cohort substantially differed from that of the clinical model (AUC: 0.896 versus 0.845, p = 0.015) and the radiomics model (AUC: 0.896 versus 0.811, p = 0.002). The Delong test in the test cohort revealed no significant difference among the three models. Conclusions: CT-based radiomics-clinical nomogram can be a useful tool for quantitatively predicting the status of muscle invasion in BCa.


  • Open Access

    Integrative machine learning algorithms for developing a consensus RNA modification-based signature for guiding clinical decision-making in bladder cancer

    by Shijun Jia, Linhan Zhai, Feng Wu, Wenzhi Lv, Xiangde Min, Shuang Zhang, Feng Li

    Objectives: Dysregulation of RNA modifications has emerged as a contributor to cancer, but the clinical implication of RNA modification-related genes remains largely unclear. The study focused on well-studied RNA modification modalities (m6A, m1A, m5C and m7G) in bladder cancer, and proposed a machine learning-based integrative approach for establishing a consensus RNA modification-based signature. Methods: Multiple publicly available bladder cancer cohorts were enrolled. A novel RNA modification-based classification was proposed via consensus clustering analysis. RNA modification-related genes were subsequently selected through WGCNA. A machine learning-based integrative framework was implemented for constructing a consensus RNA modification-based signature. Results: Most RNA modifiers were dysregulated in bladder tumours at the multi-omics levels. Two RNA modification clusters were identified, with diverse prognostic outcomes. A consensus RNA modification-based signature was established, which displayed stable and powerful efficacy in prognosis estimation. Notably, the signature was superior to conventional clinical indicators. High-risk tumours presented the activation of tumourigenic pathways, with the activation of metabolism pathways in low-risk tumours. The low-risk group was more sensitive to immune-checkpoint blockade, with the higher sensitivity of the high-risk group to cisplatin and paclitaxel. Genes in the signature: AKR1B1, ANXA1, CCNL2, OAS1, PTPN6, SPINK1 and TNFRSF14 were specially expressed in distinct T lymphocytes of bladder tumours at the single-cell level, potentially participating in T cell-mediated antitumour immunity. They were transcriptionally and post-transcriptionally modulated, and might become potentially actionable therapeutic targets. Conclusions: Altogether, the consensus RNA modification-based signature may act as a reliable and hopeful tool for improving clinical decision-making for individual bladder cancer patients.